LB Pharmaceuticals LBRX
Valuation
Multiples measured against the stock's own five-year history
Near the top of its 5-year range · 99th percentile, 5-year average -1,614.3x
#2468 of 2991 stocks by PE (1 = cheapest)
Above its usual level · 78th percentile, 5-year average 1.8x
#3905 of 5329 stocks by PB (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 3.33 | – | 1.84 | 78% (pricier than usual) | #3905 of 5329 (1 = cheapest) |
| PE | 42.42 | -6.08 | -1,614.28 | 99% (pricier than usual) | #2468 of 2991 (1 = cheapest) |
| PS | – | – | 0.00 | – | – |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on LBRX.
Sign in to join the discussion.